Kai U Chow
Overview
Explore the profile of Kai U Chow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klinsing S, Beck J, Weber K, Bornemann-Kolatzki K, Dettki M, Urban H, et al.
Acta Neuropathol Commun
. 2024 Nov;
12(1):177.
PMID: 39568088
The gold standard for precise diagnostic classification of brain tumors requires tissue sampling, which carries relevant procedural risks. Brain biopsies often have limited sensitivity and fail to address tumor heterogeneity,...
2.
Weidmann E, Hess G, Chow K, Krause S, Subklewe M, Kruse J, et al.
Leuk Lymphoma
. 2010 Feb;
51(3):447-55.
PMID: 20141439
The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable. Therefore, there is a need for improvement of treatment options. Patients with newly diagnosed (n...
3.
Atta J, Chow K, Weidmann E, Mitrou P, Hoelzer D, Martin H
Leuk Lymphoma
. 2007 Feb;
48(2):349-56.
PMID: 17325896
Although aggressive NHL in relapse after remission can still be cured by second-line treatment followed by high-dose therapy and autologous stem cell transplantation, the long-term prognosis of patients who fail...
4.
Glienke W, Chow K, Bauer N, Bergmann L
Leuk Lymphoma
. 2006 Sep;
47(8):1629-38.
PMID: 16966277
Arsenic trioxide (As2O3) induces remission in patients with acute promyelocytic leukemia (APL). To better understand molecular mechanisms of arsenic actions, this study investigated the effect of two different arsenic compounds...
5.
Rummel M, Al-Batran S, Kim S, Welslau M, Hecker R, Kofahl-Krause D, et al.
J Clin Oncol
. 2005 May;
23(15):3383-9.
PMID: 15908650
Purpose: The aim of this multicenter-study was to evaluate the progression-free survival, response rate and toxicity of the combination of bendamustine and rituximab (BR) in patients with mantle cell or...
6.
Trojan J, Kim S, Engels K, Kriener S, Mitrou P, Chow K
Anticancer Drugs
. 2004 Dec;
16(1):87-91.
PMID: 15613910
Individual response of disseminated cancer to chemotherapy is unpredictable. In vitro chemotherapy-induced apoptosis can be measured and might be a method to evaluate in vivo activity of tested drugs. In...
7.
Bergmann M, Kukoc-Zivojnov N, Chow K, Trepohl B, Hoelzer D, Weidmann E, et al.
Ann Hematol
. 2004 Aug;
83(10):646-53.
PMID: 15316756
Evaluating the functional consequences of prostate apoptosis response gene-4 (par-4) expression in CD95-induced apoptosis of neoplastic lymphocytes, we demonstrate that par-4 increases apoptosis by upregulating the CD95 receptor on the...
8.
Kukoc-Zivojnov N, Puccetti E, Chow K, Bergmann M, Ruthardt M, Hoelzer D, et al.
Exp Hematol
. 2004 Jul;
32(7):649-56.
PMID: 15246161
Objective: Prostate apoptosis response gene-4 (par-4) is deregulated in acute and chronic lymphatic leukemia. Given its pro-apoptotic role in neoplastic lymphocytes and evidence that par-4 antagonizes oncogenic Ras in solid...
9.
Chow K, Boehrer S, Napieralski S, Nowak D, Knau A, Hoelzer D, et al.
Leuk Lymphoma
. 2003 Apr;
44(1):165-73.
PMID: 12691159
The pyrimidine analogue Ara-C and the purine analogues fludarabine and cladribine (2-CdA) are essential compounds in the treatment of acute myeloid leukemia (AML). Inhibition of cell proliferation and induction of...
10.
Kim S, Zollner T, Schui D, Chow K, Sterry W, Kriener S, et al.
Leuk Lymphoma
. 2003 Apr;
44(2):281-9.
PMID: 12688346
CD4+ CD56+ neoplasia is a rare malignancy of unclarified origin. So far only 57 cases have been reported. We characterized in detail a case of CD4+ CD56+ malignancy with special...